Abacus Bioscience Raises $4.4M for Novel Cancer Vaccine Technology Led by Ex-Seagen Executives
Abacus Bioscience, a University of Washington spinout led by former Seattle Genetics veterans, raised $4.4 million to develop a novel cancer vaccine approach targeting tumor antigens to stimulate a strong immune response. Despite historical skepticism about cancer vaccines, Abacus aims to advance a new technology that activates immune cells via antibody fragments linked to tumor antigens.
No comments yet.